Companies House 16040435 2025-10-31 2025-10-31 2024-10-25 false iso4217:GBP xbrli:pure 16040435 2025-10-31 16040435 2024-10-25 2025-10-31 16040435 curr:PoundSterling 2024-10-25 2025-10-31 16040435 uk-bus:PrivateLimitedCompanyLtd 2024-10-25 2025-10-31 16040435 uk-bus:FRS102 2024-10-25 2025-10-31 16040435 uk-bus:AuditExempt-NoAccountantsReport 2024-10-25 2025-10-31 16040435 uk-bus:FullAccounts 2024-10-25 2025-10-31 16040435 uk-bus:RegisteredOffice 2024-10-25 2025-10-31 16040435 uk-bus:Director1 2024-10-25 2025-10-31 16040435 uk-bus:Director2 2024-10-25 2025-10-31 16040435 uk-bus:Director3 2024-10-25 2025-10-31 16040435 uk-bus:Director4 2024-10-25 2025-10-31 16040435 uk-bus:Director5 2024-10-25 2025-10-31 16040435 uk-bus:Director6 2024-10-25 2025-10-31 16040435 uk-bus:Director7 2024-10-25 2025-10-31 16040435 uk-bus:Director8 2024-10-25 2025-10-31 16040435 uk-bus:Director9 2024-10-25 2025-10-31 16040435 uk-bus:Director10 2024-10-25 2025-10-31 16040435 uk-bus:Director11 2024-10-25 2025-10-31 16040435 uk-bus:Director12 2024-10-25 2025-10-31 16040435 uk-bus:Director13 2024-10-25 2025-10-31 16040435 uk-bus:Director14 2024-10-25 2025-10-31 16040435 uk-bus:Director15 2024-10-25 2025-10-31 16040435 uk-bus:Director16 2024-10-25 2025-10-31 16040435 uk-bus:Director17 2024-10-25 2025-10-31 16040435 uk-bus:Director18 2024-10-25 2025-10-31 16040435 uk-bus:Director19 2024-10-25 2025-10-31 16040435 uk-bus:Director20 2024-10-25 2025-10-31 16040435 uk-bus:Director21 2024-10-25 2025-10-31 16040435 uk-bus:CompanySecretary1 2024-10-25 2025-10-31 16040435 core:AfterOneYear 2025-10-31 16040435 core:WithinOneYear 2025-10-31 16040435 core:WithinOneYear 2024-10-25 2025-10-31 16040435 core:AfterOneYear 2025-10-31 16040435 core:AfterOneYear 2024-10-25 2025-10-31 16040435 core:ShareCapital 2025-10-31 16040435 core:SharePremium 2025-10-31 16040435 core:OtherReservesSubtotal 2025-10-31 16040435 core:RevaluationReserve 2025-10-31 16040435 core:RetainedEarningsAccumulatedLosses 2025-10-31 16040435 1 2024-10-25 2025-10-31 16040435 2 2024-10-25 2025-10-31 16040435 3 2024-10-25 2025-10-31 16040435 core:LandBuildings 2024-10-25 2025-10-31 16040435 core:LandBuildings 2025-10-31 16040435 core:PlantMachinery 2024-10-25 2025-10-31 16040435 core:PlantMachinery 2025-10-31 16040435 core:FurnitureFittingsToolsEquipment 2024-10-25 2025-10-31 16040435 core:FurnitureFittingsToolsEquipment 2025-10-31 16040435 core:OfficeEquipment 2024-10-25 2025-10-31 16040435 core:OfficeEquipment 2025-10-31 16040435 core:Vehicles 2024-10-25 2025-10-31 16040435 core:Vehicles 2025-10-31 16040435 core:NetGoodwill 2024-10-25 2025-10-31 16040435 core:NetGoodwill 2025-10-31 16040435 core:IntangibleAssetsOtherThanGoodwill 2024-10-25 2025-10-31 16040435 core:IntangibleAssetsOtherThanGoodwill 2025-10-31

# ATCO PHARMA LTD

## Company Registration Number:
16040435 (England and Wales)

## Unaudited statutory accounts for the year ended 31 October 2025

## Period of accounts

## Start date: 25 October 2024

## End date: 31 October 2025

# ATCO PHARMA LTD

## Contents of the Financial Statements

for the Period Ended 31 October 2025

Directors report |
Balance sheet |
Additional notes |

# ATCO PHARMA LTD

Directors' report period ended 31 October 2025

The directors present their report with the financial statements of the company for the period ended 31 October 2025

Directors

The directors shown below have held office during the period of
26 October 2024 to 31 October 2025

amir mehdi alamgir tehrani
sarvenaz alamgirtehrani

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
30 November 2025

And signed on behalf of the board by:
Name: amir mehdi alamgir tehrani
Status: Director

# ATCO PHARMA LTD

## Balance sheet

As at 31 October 2025

| Notes | 2025
--- | --- | ---
|  | £
Called up share capital not paid: |  | 0 |
Fixed assets
Intangible assets: |  | 0 |
Tangible assets: |  | 0 |
Investments: |  | 0 |
Total fixed assets: |  | 0
Current assets
Stocks: |  | 0 |
Debtors: |  | 0 |
Cash at bank and in hand: |  | 100 |
Total current assets: |  | 100
Prepayments and accrued income: |  | 0 |
Creditors: amounts falling due within one year: |  | 0 |
Net current assets (liabilities): |  | 100
Total assets less current liabilities: |  | 100
Creditors: amounts falling due after more than one year: |  | 0 |
Provision for liabilities: |  | 0 |
Accruals and deferred income: |  | 0 |
Total net assets (liabilities): |  | 100
Capital and reserves
Called up share capital: |  | 100 |
Share premium account: |  | 0 |
Other reserves: |  | 0 |
Profit and loss account: |  | 0 |
Total Shareholders' funds: |  | 100

The notes form part of these financial statements

# ATCO PHARMA LTD

## Balance sheet statements

For the year ending 31 October 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen not to file a copy of the company's profit and loss account.

This report was approved by the board of directors on 30 November 2025
and signed on behalf of the board by:

Name: amir mehdi alamgir tehrani
Status: Director

The notes form part of these financial statements

# ATCO PHARMA LTD

## Notes to the Financial Statements

for the Period Ended 31 October 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

# ATCO PHARMA LTD

## Notes to the Financial Statements

for the Period Ended 31 October 2025

- ## 2. Employees

  | 2025
  --- | ---
  Average number of employees during the period | 0 |